Sigma-Aldrich is offering Stemgent's portfolio of lentivirus-based delivery systems for the generation of induced pluripotent stem (IPS) cells.
Dr David Smoller, PhD, president of Sigma-Aldrich's research biotech business unit, said: 'Induced pluripotent stem cells have emerged as immensely useful tools for the modelling of human diseases, research and development of therapeutics, regenerative medicine and the development of personalised cell-replacement therapies.' The reprogramming technologies offered under the terms of the agreement involve proprietary viral vectors from Stemgent, lentivirus technology from Sigma-Aldrich and Dox Inducible expression from TET Systems.
These technologies have been validated in Stemgent's laboratories and are expected to allow researchers to efficiently reprogram mouse and human cells into IPS cells, enabling the researchers to investigate and address the challenges facing the field of regenerative medicine.
The agreement with Stemgent complements Sigma-Aldrich's 1,100 products and services, which support the entire cycle of stem-cell research, including reprogramming, isolation, characterisation, expansion, differentiation, functional profiling and in-vitro/in-vivo tracking.
